German Network for Personalized Medicine (DNPM) - Evaluatio

Recruiting

• Conditions: Patients with serious, advanced cancer who have undergone guideline-based therapy and patients with rare tumors for which no guideline-based therapy exists were enrolled.

• Registration Number: DRKS00031622
• Lead Sponsor: Zentrum für Personalisierte Medizin, Universitätsklinikum Tübingen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-05-23
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 6000

Inclusion Criteria

1. Diagnosis of cancer including progression or recurrence (all cancer entities can be included)
2. Patient should be able to participate in data collection
3. Treatment at one of the participating CCC/ZPMs or patient presented there for a second opinion
4. Molecular diagnostics possible
5. Patient qualifies for the MTB of the center
6. First presentation at the MTB of the center
7. Informed consent = written consent for participation in the study and data transfer

Exclusion Criteria

Linguistic or cognitive limitations that result in inability to collect data even with assistance

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in patient management due to MTB decision (calculated based on quantitative questionnaire completed by site staff): <br>- Number of patients admitted to the MTB (T0 = day of initial presentation to the MTB)<br>- Proportion of patients with changed diagnostic strategy and/or therapy recommendation based on tumor board decisions (T1 = day of therapy decision)<br>- Proportion of patients with actually implemented changed diagnostic strategy and/or therapy (T2 = day of first therapeutic intervention)